Cargando…

Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance

Activation of EGFR signaling pathway leads to prostate cancer bone metastasis; however, therapies targeting EGFR have demonstrated limited effectiveness and led to drug resistance. miR-203 levels are down-regulated in clinical samples of primary prostate cancer and further reduced in metastatic pros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siu, Man Kit, Abou-Kheir, Wassim, Yin, Juan Juan, Chang, Yung-Sheng, Barrett, Ben, Suau, Florent, Casey, Orla, Chen, Wei-Yu, Fang, Lei, Hynes, Paul, Hsieh, Yao-Yu, Liu, Yen-Nien, Huang, Jiaoti, Kelly, Kathleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116519/ https://www.ncbi.nlm.nih.gov/pubmed/25004126

Ejemplares similares

Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance
por: Siu, Man Kit, et al.
Publicado: (2018)

Androgen receptor regulates SRC expression through microRNA-203
por: Siu, Man Kit, et al.
Publicado: (2016)

Self-Renewing Pten(-/-)TP53(-/-) Protospheres Produce Metastatic Adenocarcinoma Cell Lines with Multipotent Progenitor Activity
por: Abou-Kheir, Wassim, et al.
Publicado: (2011)

Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer
por: Tsai, Yuan-Chin, et al.
Publicado: (2018)

Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency
por: Wen, Yu-Ching, et al.
Publicado: (2022)

MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer
por: Chen, Wei-Yu, et al.
Publicado: (2014)

TMPRSS2- Driven ERG Expression In Vivo Increases Self-Renewal and Maintains Expression in a Castration Resistant Subpopulation
por: Casey, Orla M., et al.
Publicado: (2012)

MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer
por: Ghamlouche, Fatima, et al.
Publicado: (2023)

Crosstalk between COVID-19 and prostate cancer
por: Bahmad, Hisham F., et al.
Publicado: (2020)

Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms
por: Bilani, Nadeem, et al.
Publicado: (2017)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

Berberis libanotica Ehrenb Extract Shows Anti-Neoplastic Effects on Prostate Cancer Stem/Progenitor Cells
por: El-Merahbi, Rabih, et al.
Publicado: (2014)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Primary versus castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines
por: Daoud, Georges, et al.
Publicado: (2016)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Sphere-Formation Assay: Three-Dimensional in vitro Culturing of Prostate Cancer Stem/Progenitor Sphere-Forming Cells
por: Bahmad, Hisham F., et al.
Publicado: (2018)

Tyrosine kinase signalling in breast cancer
por: Hynes, Nancy E
Publicado: (2000)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Schedule of experiment R203
por: Jarlskog, G
Publicado: (1973)

Quadrupole moment of $^{203}$Fr
por: Wilkins, S G, et al.
Publicado: (2017)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

The ErbB receptor tyrosine kinases and their roles in cancer
por: Hynes, NE
Publicado: (2003)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond
por: Al Bitar, Samar, et al.
Publicado: (2023)

Tissue-specific cancer stem/progenitor cells: Therapeutic implications
por: Yehya, Amani, et al.
Publicado: (2023)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?
por: Heideman, Marinus R, et al.
Publicado: (2013)

Serenaden K. 185 & K. 203
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1990)

The decays of $^{205}$Po and $^{203}$Po
por: Astner, G, et al.
Publicado: (1972)

Health Tract No. 203: Household Knowledge
Publicado: (1865)

Health Tract No. 203: Household Knowledge
Publicado: (1864)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

A Unique Expression of Keratin 14 in a Subset of Trophoblast Cells
por: Abou-Kheir, Wassim, et al.
Publicado: (2015)

Drosophila Tet Is Expressed in Midline Glia and Is Required for Proper Axonal Development
por: Ismail, Joy N., et al.
Publicado: (2019)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
por: Wu, Shang-Gin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9gm28e7k3j3e80ff3rr7sokbgo